Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: April 2007
-
By Kevin E. Noonan — As has been reported elsewhere (see Patently O: "Rumors Continuations & Claims"), the U.S. Patent and Trademark Office appears to be ready to issue "final rules" on changing continuation application practice, said PTO’s Commissioner of Patents John Doll today at a meeting of the District of Columbia Bar…
-
By Donald Zuhn — On Tuesday, GTC Biotherapeutics, Inc. announced that it had been granted a non-exclusive worldwide license from stART Licensing, Inc. to use stART’s nuclear transfer patents and patent applications to produce therapeutic proteins in the milk of transgenic animals. GTC Biotherapeutics, Inc. commercializes therapeutic proteins through transgenic animal technology. GTC’s…
-
By Donald Zuhn — On the heels of last weekend’s report that a consortium of Middle Eastern investors and American buyout firms was preparing to pull off the world’s biggest leveraged buyout – a $50 billion buyout of Dow Chemical Co., Dow countered today that it has had no discussions concerning a leveraged…
-
By Donald Zuhn — Last month, Oncolytics Biotech Inc. announced that it had been granted U.S. Patent No. 7,186,542. The ‘542 patent, which relates to methods of producing reovirus from a cultured cells, was the nineteenth U.S. patent to be awarded to the Calgary-based biotech company. As we reported last week, Oncolytics was…
-
By Kevin E. Noonan — Single nucleotide polymorphisms (SNPs) have been detected since the beginning of the third revolution in genetics characterized by cloning, sequencing, and the various organismal genome projects (rediscovery of Mendel’s laws being the first and Watson and Crick’s elucidation of the structure of DNA being the second). SNPs were…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Bayer Healthcare AG et. al. v. Teva Pharmaceuticals U.S.A., Inc.1:07-cv-00195; filed April 5, 2007 in the District Court of Delaware Infringement of…
-
April 13, 2007 – "Of Brics & Mortar: Technological Drivers in Booming Economies" Symposium (Northwestern Journal of Technology and Intellectual Property) – Chicago, IL April 16-18, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources Group) – Orlando, FL April 19-20, 2007 – "Litigation and Enforcement in the Biotech and Pharmaceutical Industry" (GTCbio)…
-
By Donald Zuhn — On March 23, 2007, Simcere Pharmaceuticals filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock. According to a MarketWatch report, the Chinese generic drug maker is seeking to raise $120 million in the IPO. Simcere’s shares will…
-
By Donald Zuhn — On April 3, 2007, Oncolytics Biotech Inc. announced that it had been granted U.S. Patent No. 7,198,783. The ‘783 patent, which relates to methods of sensitizing neoplastic cells to irradiation by using reoviruses, is the twentieth U.S. patent to be awarded to the Calgary-based biotech company. According to the…
-
By Mark Chael — As we reported previously, Eli Lilly & Co. had been in the process of acquiring Hypnion, Inc. and its pipeline of insomnia drug candidates. On Tuesday, Lilly announced that it had completed the acquisition, which has been valued at around $315 million. With this acquisition, Lilly enhances its drug…
Patent Docs 